313 related articles for article (PubMed ID: 26178811)
21. OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis.
Wroblewski D; Jiang CC; Croft A; Farrelly ML; Zhang XD; Hersey P
PLoS One; 2013; 8(12):e84073. PubMed ID: 24367627
[TBL] [Abstract][Full Text] [Related]
22. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
[TBL] [Abstract][Full Text] [Related]
23. MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL.
Vikström IB; Slomp A; Carrington EM; Moesbergen LM; Chang C; Kelly GL; Glaser SP; Jansen JH; Leusen JH; Strasser A; Huang DC; Lew AM; Peperzak V; Tarlinton DM
Cell Death Dis; 2016 Aug; 7(8):e2345. PubMed ID: 27560714
[TBL] [Abstract][Full Text] [Related]
24. Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer.
Nakajima W; Hicks MA; Tanaka N; Krystal GW; Harada H
Cell Death Dis; 2014 Feb; 5(2):e1052. PubMed ID: 24525728
[TBL] [Abstract][Full Text] [Related]
25. Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.
Choudhary GS; Tat TT; Misra S; Hill BT; Smith MR; Almasan A; Mazumder S
Oncotarget; 2015 Jul; 6(19):16912-25. PubMed ID: 26219338
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
Kiprianova I; Remy J; Milosch N; Mohrenz IV; Seifert V; Aigner A; Kögel D
Neoplasia; 2015 Jul; 17(7):564-73. PubMed ID: 26297434
[TBL] [Abstract][Full Text] [Related]
28. Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis.
Meynet O; Bénéteau M; Jacquin MA; Pradelli LA; Cornille A; Carles M; Ricci JE
Leukemia; 2012 May; 26(5):1145-7. PubMed ID: 22076465
[No Abstract] [Full Text] [Related]
29. BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737.
Potter DS; Kelly P; Denneny O; Juvin V; Stephens LR; Dive C; Morrow CJ
Neoplasia; 2014 Feb; 16(2):147-57. PubMed ID: 24709422
[TBL] [Abstract][Full Text] [Related]
30. Pan-BH3 mimetic S1 exhibits broad-spectrum antitumour effects by cooperation between Bax and Bak.
Song T; Xue Z; Zhang Z; Shen X; Li X
Basic Clin Pharmacol Toxicol; 2013 Sep; 113(3):145-51. PubMed ID: 23557083
[TBL] [Abstract][Full Text] [Related]
31. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.
Tagscherer KE; Fassl A; Campos B; Farhadi M; Kraemer A; Böck BC; Macher-Goeppinger S; Radlwimmer B; Wiestler OD; Herold-Mende C; Roth W
Oncogene; 2008 Nov; 27(52):6646-56. PubMed ID: 18663354
[TBL] [Abstract][Full Text] [Related]
32. Comparison of in vitro antileukemic activity of obatoclax and ABT-737.
Opydo-Chanek M; Mazur L
Tumour Biol; 2016 Aug; 37(8):10839-49. PubMed ID: 26880588
[TBL] [Abstract][Full Text] [Related]
33. The ratio of Mcl-1 and Noxa determines ABT737 resistance in squamous cell carcinoma of the skin.
Geserick P; Wang J; Feoktistova M; Leverkus M
Cell Death Dis; 2014 Sep; 5(9):e1412. PubMed ID: 25210795
[TBL] [Abstract][Full Text] [Related]
34. Mcl-1 is an important therapeutic target for oral squamous cell carcinomas.
Maji S; Samal SK; Pattanaik L; Panda S; Quinn BA; Das SK; Sarkar D; Pellecchia M; Fisher PB; Dash R
Oncotarget; 2015 Jun; 6(18):16623-37. PubMed ID: 26009874
[TBL] [Abstract][Full Text] [Related]
35. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
Kunami N; Katsuya H; Nogami R; Ishitsuka K; Tamura K
Anticancer Res; 2014 Oct; 34(10):5287-94. PubMed ID: 25275021
[TBL] [Abstract][Full Text] [Related]
36. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation.
Doi K; Li R; Sung SS; Wu H; Liu Y; Manieri W; Krishnegowda G; Awwad A; Dewey A; Liu X; Amin S; Cheng C; Qin Y; Schonbrunn E; Daughdrill G; Loughran TP; Sebti S; Wang HG
J Biol Chem; 2012 Mar; 287(13):10224-10235. PubMed ID: 22311987
[TBL] [Abstract][Full Text] [Related]
37. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition.
Coloff JL; Macintyre AN; Nichols AG; Liu T; Gallo CA; Plas DR; Rathmell JC
Cancer Res; 2011 Aug; 71(15):5204-13. PubMed ID: 21670080
[TBL] [Abstract][Full Text] [Related]
38. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
39. The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737.
Boiani M; Daniel C; Liu X; Hogarty MD; Marnett LJ
J Biol Chem; 2013 Mar; 288(10):6980-90. PubMed ID: 23341456
[TBL] [Abstract][Full Text] [Related]
40. Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML.
O' Reilly E; Dhami SPS; Baev DV; Ortutay C; Halpin-McCormick A; Morrell R; Santocanale C; Samali A; Quinn J; O'Dwyer ME; Szegezdi E
Sci Rep; 2018 Oct; 8(1):15752. PubMed ID: 30361682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
